Targeted co-delivery of PD-L1 monoclonal antibody and sorafenib to circulating tumor cells via platelet-functionalized nanocarriers

• Published in: Biochemical and biophysical research communications 2023-09, Vol.671, p.335-342
• Main Authors: Da, Xuanbo, Mo, Jiantao, Li, Qiaoxin, Cao, Bangping, Huang, Jingjing, Lu, Yuxuan, Lu, Le, Fan, Meng, Lu, Hongwei
• Format: Article
• Language: English
• Subjects: Animals; Antibodies, Monoclonal - metabolism; B7-H1 Antigen - metabolism; Blood Platelets - metabolism; Cell Line, Tumor; Circulating tumor cells (CTCs); HCC; Immunotherapy; Mice; Nanomedicines; Nanoparticles; Neoplastic Cells, Circulating; Platelet membrane; Sorafenib; Targeted therapy; Tissue Distribution
• ISSN: 0006-291X; 1090-2104
• DOI: 10.1016/j.bbrc.2023.05.124

Circulating tumor cells (CTCs) can adsorb and activate platelets to form a microthrombus protective barrier around them, so that therapeutic drugs and immune cells cannot effectively kill CTCs. The platelet membrane (PM) bionic carrying drug system has the powerful ability of immune escape, and can circulate in the blood for a long time. Materials and methods: we developed platelet membrane coated nanoparticles (PM HMSNs) to improve the precise delivery of drugs to tumor sites and to achieve more effective immunotherapy combined with chemotherapy strategy. Successfully prepared aPD-L1-PM-SO@HMSNs particles, whose diameter is 95–130 nm and presenting the same surface protein as PM. Laser confocal microscopy and flow cytometry experimental results showed that the fluorescence intensity of aPD-L1-PM-SO@HMSNs was greater than SO@HMSNs that are not coated by PM. Biodistribution studies in H22 tumor-bearing mice showed that due to the combined action of the active targeting effect and the EPR effect, the high accumulation of aPD-L1-PM-SO@HMSNs in the local tumor was more effective in inhibiting tumor growth than other groups of therapeutic agents. Platelet membrane biomimetic nanoparticles have a good targeted therapeutic effect, which can effectively avoid immune clearance and have little side effects. It provides a new direction and theoretical basis for further research on targeted therapy of CTCs in liver cancer. •Constructed platelet menbrane drug-loaded nanoparticles that specifically adhere to Circulating tumor cells (CTCs).•HMSNs coated with platelet membrane can be loaded with both sorafenib and PD-L1 monoclonal antibody.•PM-HMSNs could efficiently deliver aPD-L1 toward tumor cell membrane to help recruit more immune cells to kill tumor cells.•PM-HMSNs could be adapted to prevent tumor cells from transferring to other organs through blood circulation .